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The purpose of this study was to investigate the effect of breast density on breast cancer (BC) mortality in a mammography screening
programme. The cohort included 48052 women participating in mammography screening in Copenhagen, Denmark, where biennial
screening is offered to women aged 50–69 years. We collected information for the years 1991–2001 on screening outcome,
incident BCs (screen-, interval-, and later detected), and BC deaths. Breast density was dichotomised into fatty (F) and mixed/dense
(M/D) breasts. Screening sensitivity was measured as the odds ratio of interval versus screen-detected cancer for dense versus
F breasts. Poisson regression was used to estimate the ratios for BC incidence, case fatality, and mortality between women with M/D
and F breasts. For women with M/D breasts, the odds ratio of an interval cancer was 1.62 (95% confidence interval, CI, 1.14–2.30),
and the age-adjusted rate ratios were 2.45 (95% CI 2.14–2.81) for BC incidence, 0.60 (95% CI 0.43–0.84) for case fatality, and 1.78
(95% CI 1.17–2.72) for BC mortality. The study shows that BC in women with M/D breasts is more frequent, but on average less
severe, than in women with F breasts.
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Breast density is a measure of the composition of the breast
tissue. Breasts with low density have a high proportion of fatty (F)
tissue, whereas breasts with high density have a high proportion
of epithelial and connective tissue. Mammography has a lower
sensitivity in women with mixed/dense (M/D) breasts than in
women with F breasts (Mandelson et al, 2000, Ciatto et al, 2004;
Chiarelli et al, 2006), and women with M/D breasts have a higher
incidence of breast cancer (BC) than women with F breasts
(McCormack and dos Santos Silva, 2006; Boyd et al, 2007). We
therefore examined whether breast density affects the outcome of
mammography screening using data from the organised mammo-
graphy screening programme in Copenhagen, Denmark, earlier
shown to reduce BC mortality in targeted women by 25% and in
participating women by 37% (Olsen et al, 2005).
We tested the following hypotheses: compared with women with
F breasts, (1) the sensitivity of mammography is lower in women
with M/D breasts, and (2) women with M/D breasts have a higher
BC incidence. Our results were well in accordance with those of
earlier studies. We further tested whether: (3) because of the
lower sensitivity the case fatality rate of BC patients with M/D
breasts will be higher than that of patients with F breasts, and (4)
screened women with M/D breasts will experience a higher BC
mortality than screened women with F breasts. This study is the
first to report on the effect of breast density on BC mortality in
screened women.
MATERIALS AND METHODS
This study was based entirely on data available in administrative
registers; it was approved by the Danish Data Inspection Agency.
The Copenhagen mammography screening programme started on
1 April 1991 (Vejborg et al, 2002). The programme targets women
aged 50–69 years at the start of each biennial invitation round. All
women are personally invited to participate. About 40000 women
are invited in each invitation round. From the very beginning, all
screening has taken place at one clinic dedicated to screening and
placed at one of the Copenhagen hospitals. The clinic has three
Instrumentarium mammography equipments (Instrumentanium
Corp., Imaging Division, Tuusula, Finland) changed over time
from Alpha III to Alpha RT. Over time, only two radiologists have
been in charge of the screening programme, the first one in 1991–
96, and the second (IV) still heads the programme. Attending
women are asked to fill in a short questionnaire on hormone
therapy (HRT) use, earlier breast surgery, family history of BC, and
eventual suspicion of a breast lump. These data were, however, not
entered in the database. All screens are taken by the radiographers,
and the attending women do not see the radiologist. All mammo-
grams are centrally evaluated independently by two radiologists, to
whom only the age of the women and the questionnaire answers
are available. At subsequent screens, mammograms are compared
with those taken in the earlier screening rounds.
At the first screen, all women had two views taken of each
breast, a craniocaudal and an oblique view. During the study
period, breast density was dichotomised into F breasts, equivalent
to BI-RADS (Breast Imaging Reporting and Data System
(BI-RADS) Atlas, 2008) density code 1 and part of code 2, and
M/D breasts. Women with a negative screening test and F breasts
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ywere scheduled to have only an oblique view made at the next
screen, whereas women with a negative screening test and M/D
breasts were scheduled for two views. The decision on one or two
views was based entirely on density. Density was also evaluated at
subsequent screens. The dichotomised density codes were entered
in the database for the mammography screening programme and
used in this study.
Data from the first five biennial invitation rounds were retrieved
from the administrative file of the mammography screening
programme. Data on date of death or emigration came from the
Central Population Register, on cause of death from the Cause of
Death Register, and on incident BC cases from the Cancer Register,
the Danish Breast Cancer Cooperative Group, and from the
screening data. Incident cases of BC included both invasive BC and
DCIS. Data on oestrogen receptor status were collected by the
Danish Breast Cancer Cooperative Group from local pathology
laboratories, in which primarily immunohistochemical tests were
used. A tumour was classified as positive if 10% or more of the
cells stained positive. Progesterone receptor status was available
only for 37% of invasive cancers, so these data were not included
in the analysis. The data files were linked using the unique
personal identification numbers issued to all persons with a
permanent address in Denmark.
Analysis
For the analysis of BC incidence, BC mortality and case fatality,
women diagnosed before entering the screening programme were
excluded, as were women diagnosed with BC at first screen,
because they never received a breast density code. For BC
incidence, women were followed up from their first negative
screen – taking place between 1 April 1991 and 1 April 2001 – until
BC diagnosis, death, emigration, or end of follow-up, which was on
1 April 2001. All incident BC cases during the follow-up period
were included in the analysis irrespective of whether the mode of
detection was at screening, as interval cancer up until 2 years after
last screen, or diagnosed more than 2 years after the women left
the screening programme. For case fatality, women were followed
up from date of diagnosis with BC until date of death, emigration,
or end of follow-up on 1 April 2001. For BC mortality, women were
followed up from their first negative screen until date of death,
emigration, or end of follow-up.
For the sensitivity analysis, screen-detected and interval cancers
were defined as above, and the sensitivity of mammography
screening in M/D breasts compared with that of F breasts was
calculated as the age-adjusted ratio of the odds for interval cancers
versus screen-detected cancers in the two groups (Mandelson et al,
2000; Chiarelli et al, 2006).
Person years, incident BC cases, and BC deaths were divided into
groups corresponding to the breast density status. At each screen,
the woman entered the status recorded for her at that screen, and she
remained in this status until end of follow-up unless her status
changed at a later screen; if so, she changed status. If a BC was
diagnosed at screening, the woman remained for the case fatality and
mortality analysis in the status group recorded at her earlier screen
until the end of follow-up. BC incidence and mortality were
compared between the two breast density groups, and age-adjusted
rate ratios were calculated using Poisson regression. The low breast
density group was used as the baseline. Poisson regression was used
also for comparison of the age-adjusted case fatality rates between
BC patients with M/D and F breasts, respectively, in which death
from any cause was counted as an event.
RESULTS
During the first 10 years of the Copenhagen mammography
screening programme, a total of 134640 screens were made and
989 BC cases detected, Table 1. In total, 46% of the negative
screens were taken of F breasts. This proportion declined over
time from 53% in the first round in 1991–1993 to 36% in the
fifth round in 1999–2001. This decline was most pronounced in
women aged 50–54 years at the time of screening, in which the
percentage changed from 42% in 1991–1993 to 21% in 1999–2001,
whereas only a small change was seen over time in the oldest
women. The 134650 screens were taken in a total of 48052
women, of whom 90% experienced no change in density
status during their participation in the programme, 8% experi-
enced one, and the remaining 2% of women experienced two to
four shifts.
In the F breast group, in total 158950 person years were
accumulated for the BC mortality analysis, Table 2. The 315
incident BCs, comprised 159 screen-detected, 65 interval, and 91
cancers diagnosed after leaving the screening programme. The
interval cancers constituted 29% of the total of screen-detected and
interval cancers. In total, 37 BC deaths were observed in the F
breast group, resulting in a BC mortality rate of 23 per 100000
person years. In the M/D breast group, in total 157594 person
years were accumulated. The 694 incident BCs comprised 312
screen-detected, 214 interval, and 168 cancers diagnosed after
leaving the screening programme. The interval cancers constituted
41% of the total of screen-detected and interval cancers. In total, 53
BC deaths were observed in the M/D breast group, a BC mortality
rate of 34 per 100000 person years. The age-adjusted odds ratio for
an interval cancer vs a screen-detected cancer was 1.62 (95%
confidence interval, CI, 1.14–2.30) in women with M/D breasts
compared with women with F breasts.
The BC incidence rate ratio, as estimated in the Poisson
regression using the F breast group as baseline, was 2.45 (95% CI
2.14–2.81), being 2.39 (95% CI 2.08–2.75) for invasive cancer
and 3.40 (95% CI 2.02–5.73) for DCIS, Table 3. For invasive
cancer, the rate ratios were 2.53 (95% CI 2.13–3.02) for oestrogen
receptor-positive cancers and 1.53 (95% CI 1.11–2.12) for
oestrogen receptor-negative cancers. The case fatality rate of BCs
in M/D breasts was 0.60 (95% CI 0.43–0.84) of that of BCs in F
breasts. The age-adjusted BC mortality rate ratio was 1.78 (95%
CI 1.17–2.72).
DISCUSSION
On the basis of the Copenhagen mammography screening
programme, we tested four hypotheses on differences between
M/D and F breasts. The first was confirmed, as the sensitivity of
mammography was lower with M/D than with F breasts indicated
by the risk of an interval vs a screen-detected cancer being 1.6. The
second was also confirmed, as BC incidence was 2.5 times higher
in women with M/D than in those with F breasts. The third
hypothesis was, however, not confirmed, as the relative risk (RR)
for the case fatality rate of cancers in M/D compared with F breasts
was 0.6. The fourth hypothesis concerning BC mortality was
confirmed, but the better case fatality rate partly compensated for
the higher incidence in women with M/D breasts, resulting in BC
mortality for these women being only 1.8 times that of women with
F breasts.
In this study, women were screened in the age group 50–69
years, and on average, 54% of the women had M/D breasts deemed
from the recommendation of two-view mammography at next
screen. As our cutoff point for M/D breasts included BI-RADS
density codes 4, 3, and part of code 2, this was well in accordance
with an earlier study, in which 13% of screens had BI-RADS
density code 1; 53% had code 2; and 34% had codes 3 or 4
(Kerlikowske et al, 2007). Our data showed a drift over time
towards the M/D category, which is probably partly explained by
an increasing use of HRT during the study period (Olesen et al,
1999; Løkkegaard et al, 2007).
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yAs the data were collected from comprehensive, adminis-
trative registers, the study was not affected by recall or reporting
bias. However, it only covered women attending mammo-
graphy screening, which in Copenhagen included about 80% of
targeted women (von Euler-Chelpin et al, 2006). There is,
nevertheless, no reason to expect that attending women consti-
tuted a biased sample, as women do not a priori know their breast
density.
The odds ratio, of interval versus screen-detected cancer, of
1.62 (95% CI 1.14–2.30) between the two groups, was in line
with earlier studies indicating a lower sensitivity of mammography
in M/D than in F breasts (Mandelson et al, 2000; Chiarelli et al,
2006).
The rate ratio of incident BC was 2.45 (95% CI 2.14–2.81) in
women with M/D compared with those with F breasts. Taking into
account the difference in the cutoff points used for the M/D breast
category across studies, our result was well in line with earlier
findings (McCormack and dos Santos Silva, 2006; Boyd et al, 2007).
One could argue that the increased incidence in women with
M/D breasts in our study was an artefact because of the more
Table 1 Participants in first–fifth invitation round of the mammography screening programme in Copenhagen, Denmark, 1991–2001. Women aged
50–69 years at the start of each invitation round
Outcome of screening
Breast cancer
Negative, One view in %
Invitation round Invasive DCIS Total Negative, fatty mixed/dense Others
a Total of all negative
First, 1 April 1991–25 April 1993 316 44 360 15805 14197 33 30395 53
Second, 26 April 1993–31 May 1995
b 162 21 183 14615 13779 28 28605 51
Third, 1 June 1995–24 March 1997 136 18 154 11666 13317 13 25150 47
Fourth, 25 March 1997–19 April 1999 129 18 147 10670 14602 9 25428 42
Fifth, 20 April 1999–31 March 2001 123 22 145 8985 15928 4 25062 36
Total 866 123 989 61741 71823 87 134640 46
Abbreviation: DCIS¼ductal carcinoma in situ.
aCoding errors.
bThe invitation round targeted women aged 50–71 years.
Table 2 Number of person years at risk, screen-detected breast cancers, interval breast cancers, other breast cancers, and breast cancer deaths by density
code and age at diagnosis
Age
(years)



















50–54 14811 5 4 0 9 0 31435 33 39 8 80 3
55–59 30621 24 11 8 43 3 40464 88 56 22 166 7
60–64 33710 55 15 13 83 6 30541 80 52 36 168 14
65–69 37236 53 18 12 83 12 27242 86 38 18 142 12
70–74 32072 22 17 27 66 11 21347 25 29 55 109 9
75–79 10500 0 0 31 31 5 6565 0 0 29 29 8
Total 158950 159
e 65
e 91 315 37 157594 312
e 214
e 168 694 53
Abbreviation: CI¼confidence intervals; DCIS¼ductal carcinoma in situ.
aInvasive breast cancer and DCIS.
bScreen-detected breast cancer.
cBreast cancer diagnosed o2 years
after the last screening date.
dBreast cancer diagnosed X2 years after the last screening date.
eAge-adjusted odds ratio of interval cancer versus screen-detected cancer in women
with two-view compared with women with one-view mammography 1.62 (95% CI 1.14–2.30).
Table 3 Breast cancer incidence by stage and oestrogen-receptor status, breast cancer case fatality and breast cancer mortality by density
Fatty breasts Mixed/dense
Number of cases Person years Number of cases Person years Rate ratio
a 95% confidence interval
Breast cancer incidence
Total 315 158017 694 155110 2.45 2.14–2.81
Invasive only 296 158017 634 155110 2.39 2.08–2.75
DCIS only 19 158017 60 155110 3.40 2.02–5.73
Invasive breast cancer incidence
Oestrogen receptor positive 188 158017 421 155110 2.53 2.13–3.02
Oestrogen receptor negative 64 158017 94 155110 1.53 1.11–2.12
Oestrogen receptor unknown 44 158017 119 155110 3.05 2.15–4.33
Breast cancer case fatality 60
b 1988 86 4725 0.60 0.43–0.84
Breast cancer mortality 37
c 158950 53 157594 1.78 1.17–2.72
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yintensive screening using two-view mammography. If this was the
case, a greater sensitivity in this group would be expected, which
was not so.
Despite the lower sensitivity of mammography screening in M/D
than in F breasts, we found that patients with M/D breasts had a
better survival, with a case fatality rate ratio of 0.60 (95% CI
0.43–0.84). Using an alternative calculation with competing
risks only slightly changed the case fatality rate to 0.56 (95% CI
0.36–0.87). Including only deaths from BC gave a case fatality rate
ratio of 0.53 (95%CI 0.34–0.82). An earlier study indicated a
slightly worse BC-specific survival for BI-RADS category 2 cancers
than for category 1, 3, and 4 cancers (Porter et al, 2007).
Although M/D breasts were associated with 2.5 times the risk of
BC compared with F breasts, they ended up with a BC mortality of
only 1.8 times higher. Data on BC mortality by breast density have
not been reported earlier, although hormone use is known to delay
breast tissue transition from M/D to F (Persson et al, 1997).
Current hormone users at recruitment to the Million Women
Study had, during a follow-up period of about 4 years, a relative
risk of BC incidence of 1.66 (95% CI 1.60–1.72) compared with
never users, whereas their relative BC mortality risk was only 1.22
(95%CI 1.05–1.41) (Beral et al, 2003). A similar pattern was seen in
the Danish Nurses’ Health Study, in which the current HRT use
was associated with a rate ratio of 2.42 (95% CI 1.81–3.26) for BC
incidence and of 1.97 (95% CI 1.14–3.42) for BC mortality
(Stahlberg et al, 2005).
The excess BC risk in women with M/D breasts came
mainly from oestrogen receptor-positive tumours, RR 2.53 (95%
CI 2.13–3.02), although these women also had an excess risk of
oestrogen receptor-negative tumours, RR 1.53 (95% CI 1.11–2.12).
This accorded with data from an earlier study (Ziv et al, 2004).
Oestrogen receptor-positive BC patients have a better 5-year
survival than oestrogen receptor-negative patients (Bentzon et al,
2008), and the oestrogen receptor status data in our study were
therefore in line with our finding on case fatality.
Participants in the Copenhagen mammography screening
programme on average experienced a 37% lower BC mortality
than expected in the absence of screening (Olsen et al, 2005).
A special effort using two-view mammography was made to
diagnose BC in women with M/D breasts, but was, however, not
sufficient to bring the BC mortality of screening participants with
M/D breasts in line with that of participants with F breasts. This is
not surprising, as the sensitivity despite the special effort was
lower in women with M/D breasts than in women with F breasts.
This study has shown that, although BC is more frequent in
women with M/D than in those with F breast, the BCs of women
with M/D breasts seem on average to be less severe.
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